Here’s what you should know.
1. Renzapride is a prokinetic agent for the gastrointestinal tract.
2. EndoLogic plans to develop the compound to treat gastroparesis.
3. Renzapride completed a phase III trial where it demonstrated a small but statistically significant benefit in constipation-dominant irritable bowel syndrome patients.
4. Alizyme halted the drug’s development because of its small impact.
5. Only metoclopramide is currently FDA-approved to treat gastroparesis, and it has severe side effects, which limits its use. If Renzapride earns FDA approval, it would be a safer alternate treatment.
More articles on gastroenterology/endoscopy:
Dr. Theresa Ruddy joins Oswego Health: 4 notes
5 most read GI/endoscopy stories — Dec. 26 to Dec. 30, 2016
GI leader to know: Dr. Michael Brody of Cary Gastroenterology Associates
